How Does Smoking Impact High Blood Pressure Risk?
Smoking causes a temporary rise in blood pressure, but does that impact hypertension risk over the course of a lifetime?
Smoking causes a temporary rise in blood pressure, but does that impact hypertension risk over the course of a lifetime?
Patients who have chronic kidney disease and pulmonary hypertension are at a greater risk for a variety of adverse outcomes, according to new research.
Exercise intolerance is common in patients with chronic thromboembolic pulmonary hypertension after undergoing pulmonary endarterectomy, a new study finds.
The implantable Aria CV Pulmonary Hypertension System has received a breakthrough device designation from the FDA, according to the manufacturer Aria CV.
Read MoreAcceleron Pharma’s investigational treatment for pulmonary arterial hypertension showed positive outcomes in a mid-stage trial, the company announced on Monday.
Read MoreNew research found that the cardiac arrhythmia treatment Tikosyn (dofetilide) may be used for treatment of pulmonary arterial hypertension (PAH).
Read MoreFor patients with pulmonary arterial hypertension, updating the REVEAL risk calculator to include all-cause hospitalization was a better discriminator of risk than existing risk stratification tools.
Read MorePatients with pulmonary arterial hypertension (PAH) associated with systemic sclerosis (SSc) who...
Read MorePatients newly diagnosed with pulmonary arterial hypertension treated with macitentan and tadalafil combination therapy showed hemodynamic progress, as well as improvements in function and risk profile.
Read MoreFor patients with idiopathic interstitial pneumonia-associated pulmonary hypertension, treatment with riociguat (Adempas) was not beneficial compared to placebo, and increased adverse events.
Read MoreSelexipag could improve functional status associated with chronic obstructive pulmonary disease (COPD)among patients with pulmonary hypertension (PH), according to findings from a new study.In trial data presented at...
Read MoreScientists have identified a molecular pathway that contributes to the development of pulmonary arterial hypertension (PAH), a severe, often fatal condition that has no cure. The discovery, published Sept. 12, 2019,...
Read MoreSoniVie has been granted breakthrough device designation from the US FDA for their device to treat patients with pulmonary arterial hypertension (PAH).
Read MoreIn addition to suppressing tumors, the protein tuberous sclerosis complex 2 (TSC2) may play a role in preventing or treating pulmonary arterial hypertension (PAH).
Read MoreTreatment with selexipag versus placebo improved clinical outcomes in patients with pulmonary arterial hypertension (PAH) regardless of the time from diagnosis to drug initiation.
Read More